AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration has granted 510(k) clearance f
Search
MEDIA
MEDIA - NEWS AND UPCOMING EVENTS
Media Contact:
Julie A. Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca 416-951-7988
Category: 2012
Interface Biologics a part of Life Sciences Ontario (LSO) promotional video showcasing the many strengths and assets that Ontario's diverse life sciences sector has to offer.
Toronto, ON, Canada, September 6, 2012 – Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that AngioDynamics has been granted 510(k) clearance by the U.S. Foo
September 17, 2012 – What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.
October 2, 2012 – Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors. Ms. Beach Lin is an experien